Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient-controlled remimazolam sedation versus midazolam-based sedation for outpatient colonoscopy
2026-525809-13-00Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam, midazolam and alfentanil (2 arms), sponsored by Capital Region of Denmark. Primary endpoint: Composite primary endpoint. Planned start Oct 2026; status: authorised.
02
Drugs
remimazolammidazolamalfentanil
Beyond the preview
Go deeper on 2026-525809-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525809-13-00.